Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
gpASIT+TM with or without Adjuvant in Hay Fever
NCT01506375Phase 2Completed
- Sponsor
- TOOLS Life Science
- Start
- Nov 2011
- Primary completion
- Jan 2013
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of gpASIT+ in Seasonal Allergic Rhinoconjunctivitis (SAR) (2 arms), sponsored by TOOLS Life Science. Primary endpoints: Safety of the treatment and Clinical tolerability of the treatment at 4 weeks. Started Nov 2011; status: completed.
02
Drugs
gpASIT+
03
Conditions
Seasonal Allergic Rhinoconjunctivitis (SAR)
Beyond the preview
Go deeper on NCT01506375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01506375.